美國REBOA（主動脈內球囊封堵）市場：市場規模、佔有率、趨勢分析（按最終用途）、細分市場預測（2025-2030 年）

美國REBOA 市場的規模與趨勢：

2024 年美國REBOA（主動脈內球囊封堵）市場規模價值 720 萬美元，預估 2025 年至 2030 年期間複合年成長率為 23.6%。

Primetime Medical和Emergency Scientific等主要企業正在透過策略聯盟、併購推動美國的REBOA設備創新。具有里程碑意義的 REBOA 導管便利套件等產品提高了手術效率，而最近獲得的 FDA核准將推動市場成長。這些進步提高了可近性和有效性，擴大了 REBOA（主動脈內球囊切除術）設備的市場影響。

交通事故、跌倒、暴力等造成的創傷性損傷增加是推動美國REBOA 市場發展的關鍵因素。嚴重病例的激增增加了對 REBOA 等有效的緊急干預措施的需求。因此，這些救生設備的進步和採用不斷擴大。根據美國勞工統計局（BLS）的數據，2022年美國發生了5,486起致命工作場所傷害，比2021年增加了5.7％。交通事故是第一大死因，佔所有死亡人數的37.7％。 2023年，致命工作場所事故數量下降3.7％至5,283起，其中交通事故仍然是最常見的原因，佔所有死亡人數的36.8％。

醫療技術的進步大大提高了 REBOA 手術的安全性和有效性。技術創新，包括改進的球囊設計、先進的導管系統和改進的成像，可以實現更精確的放置和監測。這些改進改善了患者的治療效果，並增加了 REBOA 在創傷護理中的應用。例如，2024 年 6 月，總部位於猶他州的 Emergency Scientific 公司在獲得 FDA 的 510(k) 批准後宣布首次使用其具有里程碑意義的 REBOA 導管。此導管用於暫時閉塞大血管以控制緊急出血。與傳統方法相比，其先進的設計提高了咬合精度，同時減少了併發症。

醫療保健支出的增加正在推動美國REBOA 產業的擴張。對先進醫療技術和創傷護理的投資增加正在推動 REBOA 設備的採用。這種成長支持了更好的緊急干預和改善的患者治療效果。根據美國醫療保險和醫療補助服務中心的數據，2023年美國醫療支出將達到4.9兆美元，較2022年的4.6%成長7.5%。醫療保險和私人醫療保險支出的成長速度超過2022年。 2023年，衛生部門在經濟中的佔有率將達到17.6%，與2022年的17.4%相當，但低於2020年和2021年新冠疫情最嚴重時期的佔有率。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. REBOA（主動脈內球囊鉗）市場：促進因素、趨勢與範圍

• 市場聯動展望
  • 母市場展望
  • 相關/附隨市場展望
• 市場動態
  • 市場促進因素分析
  • 市場限制分析
• 美國REBOA（主動脈內球囊封堵）市場：分析工具
  • 產業分析：波特五力分析
  • PESTEL 分析

第 4 章。美國REBOA（主動脈內球囊封堵）市場：按最終用途進行的估計和趨勢分析

• 按最終用途分類的市場佔有率（2024 年和 2030 年）
• 細分儀表板
• 美國REBOA（主動脈內球囊封堵）市場：依最終用途分類的前景
• 按類型分類的市場規模預測及趨勢分析（2018-2030）
  • 主動脈閉塞
  • 心臟麻痹
  • TCCC（戰術性戰鬥傷患護理）

第5章 競爭格局

• 公司/競爭對手分類
• 供應商概況
  • 主要企業熱圖分析（2024年）
• 公司簡介
  • Prytime Medical Devices, Inc
  • Emergency Scientific, LLC
  • Qx Medical
  • Front Line Medical Technologies

U.S. REBOA Market Size & Trends:

The U.S. resuscitative endovascular balloon occlusion of the aorta market size was valued at USD 7.2 million in 2024 and is projected to grow at a CAGR of 23.6% from 2025 to 2030. Key players such as Prytime Medical and Emergency Scientific, LLC drive REBOA device innovation in the U.S. through strategic collaborations, mergers, and acquisitions. Products like the Landmark REBOA Catheter convenience kit enhance procedural efficiency, while recent FDA approvals boost market growth. These advancements improve accessibility and effectiveness, expanding the market presence of resuscitative endovascular balloon occlusion of the aorta (REBOA) devices.

The growing number of traumatic injuries from road accidents, falls, and violence is a key factor fueling the U.S. REBOA market. This surge in critical cases increases the demand for effective emergency interventions such as REBOA. As a result, advancements and adoption of these life-saving devices continue to expand. According to the U.S. Bureau of Labor Statistics (BLS), in 2022, there were 5,486 fatal work injuries in the United States, marking a 5.7% increase from 2021. Transportation incidents were the leading cause, accounting for 37.7% of these fatalities. In 2023, the number of fatal work injuries decreased by 3.7% to 5,283, with transportation incidents remaining the most frequent cause, comprising 36.8% of fatalities.

Advancements in medical technology have greatly improved the safety and effectiveness of REBOA procedures. Innovations such as enhanced balloon designs, advanced catheter systems, and improved imaging allow for more precise placement and monitoring. These improvements lead to better patient outcomes and increased adoption of REBOA in trauma care. For instance, in June 2024, Utah-based Emergency Scientific announced the first use of its Landmark REBOA catheter after receiving FDA 510(k) clearance. The device is designed for temporary occlusion of large vessels to control emergency hemorrhages. Its advanced design improves occlusion precision while reducing complications compared to traditional methods.

Increasing healthcare spending is fueling the expansion of the U.S. REBOA industry. Higher investments in advanced medical technologies and trauma care are boosting the adoption of REBOA devices. This growth supports better emergency interventions and improved patient outcomes. According to the Centers for Medicare & Medicaid Services, in 2023, healthcare spending in the U.S. reached USD 4.9 trillion, marking a 7.5% increase, up from 4.6% in 2022. Medicare and private health insurance spending grew faster than in 2022. In 2023, the health sector accounted for 17.6% of the economy, comparable to 17.4% in 2022, but this figure is lower than the shares recorded in 2020 and 2021 at the height of the COVID-19 pandemic.

U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. resuscitative endovascular balloon occlusion of the aorta market report based on end use:

• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Aortic Occlusion
• Cardiac Arrest
• Tactical Combat Casualty Care

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. End use
  • 1.2.2. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Legal landscape
    • 3.3.2.6. Environmental landscape

Chapter 4. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market: End Use Estimates & Trend Analysis

• 4.1. End Use Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. resuscitative endovascular balloon occlusion of the aorta market By End Use Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Aortic Occlusion
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cardiac Arrest
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Tactical Combat Casualty Care
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Company/Competition Categorization
• 5.2. Vendor Landscape
  • 5.2.1. Key company heat map analysis, 2024
• 5.3. Company Profiles
  • 5.3.1. Prytime Medical Devices, Inc
    • 5.3.1.1. Company overview
    • 5.3.1.2. Financial performance
    • 5.3.1.3. Product benchmarking
    • 5.3.1.4. Strategic initiatives
  • 5.3.2. Emergency Scientific, LLC
    • 5.3.2.1. Company overview
    • 5.3.2.2. Financial performance
    • 5.3.2.3. Product benchmarking
    • 5.3.2.4. Strategic initiatives
  • 5.3.3. Qx Medical
    • 5.3.3.1. Company overview
    • 5.3.3.2. Financial performance
    • 5.3.3.3. Product benchmarking
    • 5.3.3.4. Strategic initiatives
  • 5.3.4. Front Line Medical Technologies
    • 5.3.4.1. Company overview
    • 5.3.4.2. Financial performance
    • 5.3.4.3. Product benchmarking
    • 5.3.4.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. resuscitative endovascular balloon occlusion of the aorta market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. resuscitative endovascular balloon occlusion of the aorta market: Market outlook
• Fig. 10 U.S. resuscitative endovascular balloon occlusion of the aorta competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 U.S. resuscitative endovascular balloon occlusion of the aorta market driver impact
• Fig. 15 U.S. resuscitative endovascular balloon occlusion of the aorta market restraint impact
• Fig. 16 U.S. resuscitative endovascular balloon occlusion of the aorta market strategic initiatives analysis
• Fig. 17 U.S. resuscitative endovascular balloon occlusion of the aorta market: End use movement analysis
• Fig. 18 U.S. resuscitative endovascular balloon occlusion of the aorta market: End use outlook and key takeaways
• Fig. 19 Aortic occlusion market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Cardiac arrest market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Tactical combat casualty care market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Market share of key market players- U.S. resuscitative endovascular balloon occlusion of the aorta market